256 related articles for article (PubMed ID: 38050252)
21. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
Riley MM; San P; Lok E; Swanson KD; Wong ET
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
[TBL] [Abstract][Full Text] [Related]
22. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
[TBL] [Abstract][Full Text] [Related]
23. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
Dono A; Mitra S; Shah M; Takayasu T; Zhu JJ; Tandon N; Patel CB; Esquenazi Y; Ballester LY
J Neurooncol; 2021 May; 153(1):153-160. PubMed ID: 33881725
[TBL] [Abstract][Full Text] [Related]
24. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).
Shams S; Patel CB
J Mol Cell Biol; 2022 Dec; 14(8):. PubMed ID: 35973687
[TBL] [Abstract][Full Text] [Related]
25. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract][Full Text] [Related]
26. A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
Kumthekar P; Lyleroehr M; Lacson L; Lukas RV; Dixit K; Stupp R; Kruser T; Raizer J; Hou A; Sachdev S; Schwartz M; Pa JB; Lezon R; Schmidt K; Amidei C; Kaiser K
BMC Cancer; 2024 Apr; 24(1):527. PubMed ID: 38664630
[TBL] [Abstract][Full Text] [Related]
27. Progress and prospect in tumor treating fields treatment of glioblastoma.
Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
[TBL] [Abstract][Full Text] [Related]
28. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
29. Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Gött H; Kiez S; Dohmen H; Kolodziej M; Stein M
Childs Nerv Syst; 2022 Sep; 38(9):1791-1796. PubMed ID: 35181800
[TBL] [Abstract][Full Text] [Related]
30. The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes.
Rehman AA; Elmore KB; Mattei TA
Neurosurg Focus; 2015 Mar; 38(3):E14. PubMed ID: 25727223
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
32. Tumor Treating Fields Alter the Kinomic Landscape in Glioblastoma Revealing Therapeutic Vulnerabilities.
Jones AB; Schanel TL; Rigsby MR; Griguer CE; McFarland BC; Anderson JC; Willey CD; Hjelmeland AB
Cells; 2023 Aug; 12(17):. PubMed ID: 37681903
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Nishikawa R; Yamasaki F; Arakawa Y; Muragaki Y; Narita Y; Tanaka S; Yamaguchi S; Mukasa A; Kanamori M
Jpn J Clin Oncol; 2023 Apr; 53(5):371-377. PubMed ID: 36647599
[TBL] [Abstract][Full Text] [Related]
34. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Schwartz MA; Onuselogu L
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
36. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
37. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Rominiyi O; Collis SJ
Mol Oncol; 2022 Jan; 16(1):11-41. PubMed ID: 34036721
[TBL] [Abstract][Full Text] [Related]
38. Skin toxicities associated with tumor treating fields: case based review.
Lukas RV; Ratermann KL; Wong ET; Villano JL
J Neurooncol; 2017 Dec; 135(3):593-599. PubMed ID: 28849343
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort.
She L; Gong X; Su L; Liu C
Front Neurol; 2022; 13():1042888. PubMed ID: 36698900
[TBL] [Abstract][Full Text] [Related]
40. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
